Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Durvalumab Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT06503614Phase 2Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, monalizumab in non-muscle-invasive bladder cancer (NMIBC). Started Feb 2025; status: recruiting.
02
Drugs
durvalumabmonalizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06503614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503614.